In our second approach, Kaplan-Meier survival curve revealed lower probability of overall survival (OS) in breast tumor patients with higher CSC (NANOG) (p < 0.05) and Treg (FOXP3) (p < 0.05) signature genes (Fig. 1B), in concordance with earlier reports [36–38]. This evidence concerns the gene NANOG and breast neoplasm.